Please Subscribe to get a daily link to Pat's blog via email

Subscribe!

Your privacy is important to us. We will never spam you and keep your personal data secure.

Monthly Archives: June 2012

Home/2012/June
28 06, 2012

Myeloma survivor, Don Wright, completes marathon in Alaska

Tags: , |0 Comments

Remember my good friend Don Wright? Minnesota Don’s inspirational story goes national Don lives with his lovely wife and daughter in St. Paul, Minnesota.  The three of them always travel together.  They are pictured here following an event several months back. (Don is pictured here, wearing red.  His daughter, Sarah, that he lovingly calls "Sweet

26 06, 2012

Isn’t it ironic? Would I like Dad’s desk?

2 Comments

Pattie and I just returned after traveling to the Chicago area to surprise my father on his 90th birthday. Pattie works full time and couldn’t get much time off, so we flew-up on Saturday and flew home last night. I could tell that it meant so much to my father for us to visit--especially since

25 06, 2012

Mainstream media’s take on the FDA/carfilzomib hearings

Tags: , , |0 Comments

OK.  Enough about the importance of individualized d0sing--and how well it works--for now.  But trust me.  We will revisit this issue often.  And Gary, when you are ready to roll your program out, my legions of readers will be here to help! Want to read an excellent, comprehensive review about the FDA committee hearings over

23 06, 2012

Exciting new research helps prove timing can be everything!

Tags: , , , , , |2 Comments

Have you read yesterday's post?  Think the timing of when and how you use a drug isn't important?  Check-out this research development which relies on timing to help break-down myeloma cells: Stopping and Starting Cancer Cell Cycle Weakens and Defeats Multiple Myeloma ScienceDaily (June 21, 2012) — Weill Cornell Medical College researchers have devised an

22 06, 2012

Immunotherapy: The good, the bad and the ugly. Part Three: The UGLY!

Tags: , , , , , |13 Comments

In theory, immunotherapy is a good thing--a very good thing. And following news at ASCO about a number of positive advances in the field--including using targeted antibodies and sophisticated drug and immuno combinations to fight everything fro breast cancer to multiple myeloma--excitement was running high in Chicago earlier this month. I wrote three or four

20 06, 2012

FDA Advisory Committee recommends accelerated approval of carfilzomib!

Tags: , , , |9 Comments

Today's long awaited FDA Advisory Committee meeting focused on carfilzomib's role as a salvage therapy for patients who have become refractory to Revlimid and/or Velcade. Dr. Anderson from Dana-Farber and Harvard Medical School, spoke in support of the drug. He reviewed the study results that were used to qualify carfilzomib for FDA fast track approval

20 06, 2012

Tip for staying positive: Never have a bad day!

Tags: |4 Comments

Readers, friends and family often ask me, "Pat, how do you stay so positive?" Well, you might not know it from the down-in-the-dumps post I shared with you yesterday, but I rarely--if ever--have a bad day. What's my secret? I don't think of time in 24 hour increments.  After all, 24 hours is a lot

18 06, 2012

Transplant timing questions continue to top my “most commonly asked question” list

Tags: , |7 Comments

  I hope everyone had a wonderful Father's Day Weekend! Apparently, families of multiple myeloma patients weren't all relaxing at the beach. I often receive emails asking for my opinion about if and when a multiple myeloma patient should undergo an autologous (using a patient's own stem cells) stem cell transplant--holiday weekend or not. Questions

16 06, 2012

Amazing nanoparticle technology may improve myeloma therapy

Tags: , , |6 Comments

What do nanoparticles have to do with multiple myeloma? Apparently, researchers at Notre Dame University are working on ways to short-circuit myeloma's ability to develop drug resistance. EXCELLENT!  As I have shared here a number of different times, overcoming drug resistance is the key to truly turning multiple myeloma into a manageable, chronic disease. But